What does the research say about beta-oxidation?
Beta-oxidation is the mitochondrial pathway that breaks fatty acyl chains into acetyl-CoA. Here we summarise what laboratory and animal studies report about its regulation, its measurement, and its role in skeletal muscl
Beta-oxidation is the formal name for the mitochondrial catabolic pathway in which fatty acyl-CoA molecules are shortened two carbons at a time, releasing acetyl-CoA, reduced electron carriers and, in the case of unsaturated or odd-chain substrates, auxiliary products. Synonyms in the literature include fatty acid oxidation (FAO), fatty acid beta-oxidation and, less precisely, fat oxidation. The pathway is not a single enzyme but a cycle of four recurring reactions — oxidation, hydration, oxidation and thiolysis — catalysed by acyl-CoA dehydrogenases, enoyl-CoA hydratases, 3-hydroxyacyl-CoA dehydrogenases and thiolases, with chain-length-specific isoforms distributed between the mitochondrial matrix and the inner membrane. The evidence block supplied for this page does not give a sequence, formula or molecular weight for the pathway as a whole, and none is asserted here.
The work summarised below centres on the regulation of substrate flux through mitochondrial energy metabolism, including the incretin receptor and secretagogue systems that have been studied for their effects on fatty acid handling in liver and muscle.
Research Studies
GHRP-6 and post-infarct ventricular remodelling in rats
Growth hormone-releasing peptide-6 (GHRP-6) is a growth hormone secretagogue hexapeptide. In a permanent coronary ligation model, rats were assigned to sham-operated, infarcted plus saline, or infarcted plus GHRP-6 groups, with treatment beginning after surgery and continuing for seven days. The authors had previously established 0.4 mg/kg as the minimum effective dose for enhancing inotropy by echocardiographic criteria in healthy rats, and applied that dose in the infarct model, which produces left ventricular wall thinning and ballooning. Echocardiographic assessment was performed on day 7 [1]. This is an animal study; no human cardiac endpoint is reported in the evidence supplied.
Ergogenic supplements and skeletal muscle energy metabolism in cyclists
A structured review of the supplement literature for cycling performance searched PubMed, Scopus and Web of Science for peer-reviewed human studies published up to May 2025, restricted to English-language reports evaluating endurance performance, recovery or physiological function. The review describes direct ergogenic effects as being achieved primarily through modulation of skeletal muscle energy metabolism, noting that during exercise adenosine triphosphate resynthesis depends on the coordinated use of substrate pools [2]. The review is a synthesis of human trials; individual findings within it are not reproduced here.
PYY3-36 and semaglutide-mediated mitochondrial modulation in MASLD
In obese rats, a study examined the cellular effects of glucagon-like peptide 1 receptor signalling in metabolic dysfunction-associated steatotic liver disease, a frequent comorbidity of obesity, and reported that PYY3-36 potentiated semaglutide-mediated mitochondrial modulation [3]. This is a reference-only item: it supports the wider theme of mitochondrial substrate handling in liver, and is not the subject of this page.
Comparing the models used across the evidence
| Study | Model | Intervention | Duration |
|---|---|---|---|
| [1] | Rat, permanent coronary ligation | GHRP-6 0.4 mg/kg vs saline | 7 days |
| [2] | Human cyclists (reviewed trials) | Ergogenic and medical supplements | Up to May 2025 literature |
| [3] | Obese rats, MASLD | Semaglutide with PYY3-36 | Not stated in evidence |
What the evidence does not establish
None of the supplied sources reports a direct measurement of beta-oxidation flux as a primary endpoint. The cardiac work reports echocardiographic parameters in rats [1]; the cycling review reports endurance, recovery and physiological outcomes in humans [2]; the MASLD work reports mitochondrial modulation in obese rats [3]. Any statement that a compound increases, decreases or otherwise alters beta-oxidation rates in humans is not supported by this evidence block and is therefore not made here.
Species and translation status
- Animal-only: the post-infarct cardiac work [1] and the MASLD mitochondrial work [3].
- Human data: the cycling supplement review [2], which is a synthesis rather than a primary trial.
- In vitro data: none is supplied in this evidence block.
If you are reading this for personal health reasons
The materials discussed on this page are sold for laboratory research use only. We do not provide dosing information, medical guidance or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation
- [2] A comprehensive review of the physiology and evidence base to guide the use of ergogenic and medical supplements for enhanced cycling performance
- [3] PYY3-36 potentiates semaglutide-mediated mitochondrial modulation in MASLD